Prospects of tetrapeptide application in treatment of chronic bronchitis: molecular mechanisms
V. Kh. Khavinson, G. A. Ryzhak, N. S. Linkova, V. V. Ashapkin, A. O. Drobintseva, V. S. Basharina, B. F. Vanyushin · 2014 · Molecular Medicine. 2014;(6):14–20
Reported findings and study design
In a 30-day comparison, vital capacity rose from 3,650.5 to 4,130.4 mL with oral Bronchogen plus standard care, versus 3,735.6 to 3,805.3 mL with standard care. Expiratory forced vital capacity rose from 2,740.7 to 3,800.7 mL versus 2,850.0 to 3,210.9 mL.
78 patients aged 34–65 with chronic bronchitis and an asthmatic component in remission; adjunctive Bronchogen 58, standard-care controls 20. Stratified randomization reported.
Dose, route and schedule
Two capsules containing 0.1 mg active substance each, twice daily with meals for 30 days (0.4 mg/day), added to standard treatment. Reported study method, not a personal-use recommendation.
Protocol source ↗ · Original PDF p.17 clinical methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Vital capacity, mean ± reported dispersion | 3,650.5 ± 295.4 → 4,130.4 ± 121.1 mL | Control: 3,735.6 ± 274.4 → 3,805.3 ± 276.7 mL · Baseline → day 30 |
| Expiratory forced vital capacity | 2,740.7 ± 120.3 → 3,800.7 ± 116.1 mL | Control: 2,850.0 ± 135.3 → 3,210.9 ± 136.6 mL · Baseline → day 30 |
| Total lung capacity | 4,812.4 ± 254.10 → 5,300.5 ± 171.8 mL | Control: 4,854.3 ± 246.8 → 5,120.2 ± 156.3 mL |
| Subjective improvement | 86% in the active group | General wellbeing/symptoms; no corresponding control proportion supplied |
Table 3 · Respiratory measurements (mL)
| Measure | Control baseline | Bronchogen baseline | Control after | Bronchogen after |
|---|---|---|---|---|
| Vital capacity | 3735.6 ± 274.4 | 3650.5 ± 295.4 | 3805.3 ± 276.7 | 4130.4 ± 121.1* |
| Total lung capacity | 4854.3 ± 246.8 | 4812.4 ± 254.10 | 5120.2 ± 156.3 | 5300.5 ± 171.8* |
| Expiratory forced vital capacity | 2850.0 ± 135.3 | 2740.7 ± 120.3 | 3210.9 ± 136.6* | 3800.7 ± 116.1* |
Values transcribed from the original table. * marks p<0.05 in the source, but the clinical comparison reference is not clearly specified. Both groups improved on forced vital capacity; this is not an FEV1 table.
No placebo or blinding described. The table measures forced vital capacity, not FEV1. Its significance footnote does not clearly resolve every within- versus between-group comparison. Oral capsule findings cannot be transferred to injectable or differently formulated products.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- No placebo or blinding described. The table measures forced vital capacity, not FEV1. Its significance footnote does not clearly resolve every within- versus between-group comparison. Oral capsule findings cannot be transferred to injectable or differently formulated products.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Original PDF, clinical table checked
Source access and review scope
Original publisher PDF methods and clinical table checked; table visually verified.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Journal publication
Citation and original source
Original source: V. Kh. Khavinson, G. A. Ryzhak, N. S. Linkova, V. V. Ashapkin, A. O. Drobintseva, V. S. Basharina, B. F. Vanyushin. Prospects of tetrapeptide application in treatment of chronic bronchitis: molecular mechanisms Molecular Medicine. 2014;(6):14–20 2014.
Molekul research summary: https://molekul.io/research/bronchogen-bronchitis-2014. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry